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Proteins PRPF31, PRPF3 and PRPF8 (RP-PRPFs) are ubiquitously expressed components of the spliceo-
some, a macromolecular complex that processes nearly all pre-mRNAs. Although these spliceosomal pro-
teins are conserved in eukaryotes and are essential for survival, heterozygous mutations in human RP-
PRPF genes lead to retinitis pigmentosa, a hereditary disease restricted to the eye. Using cells from patients
with 10 different mutations, we show that all clinically relevant RP-PRPF defects affect the stoichiometry of
spliceosomal small nuclear RNAs (snRNAs), the protein composition of tri-small nuclear ribonucleoproteins
and the kinetics of spliceosome assembly. These mutations cause inefficient splicing in vitro and affect con-
stitutive splicing ex-vivo by impairing the removal of at least 9% of endogenously expressed introns.
Alternative splicing choices are also affected when RP-PRPF defects are present. Furthermore, we show
that the steady-state levels of snRNAs and processed pre-mRNAs are highest in the retina, indicating a par-
ticularly elevated splicing activity. Our results suggest a role for PRPFs defects in the etiology of PRPF-linked
retinitis pigmentosa, which appears to be a truly systemic splicing disease. Although these mutations cause
widespread and important splicing defects, they are likely tolerated by the majority of human tissues but are
critical for retinal cell survival.
INTRODUCTION
Heterozygous mutations in genes PRPF31 (RP11, OMIM
606419), PRPF8 (RP13, OMIM 600059) and PRPF3 (RP18,
OMIM 601414) cause retinitis pigmentosa (RP, OMIM
268000) (1–3), a group of hereditary disorders characterized
by progressive degeneration of the photoreceptors, the light-
sensing cells in the retina (4).
All of these genes, as well as RP genes SNRNP200 and RP9
(5–8), are involved in pre-mRNA splicing, a process by which
introns are removed from pre-mRNA and exons are joined to
produce mature mRNA. Pre-mRNA processing resulting in a
single form of mRNA is defined as constitutive splicing. Con-
versely, alternative splicing (AS) yields multiple mature
transcripts from the same pre-mRNA. In humans, AS is a
major contributor to increased protein diversity since .90%
of primary transcripts are alternatively spliced (9,10).
Splicing is performed by the spliceosome, a macromolecular
complex that contains five uridine-rich small nuclear RNAs (U
snRNAs) and over 100 proteins (reviewed in 11). These
snRNAs associate with specific proteins to form small nuclear
ribonucleoproteins (snRNPs). The U1, U2, U4 and U6 snRNP
compose the major (U2-type) spliceosome, processing .99%
of all introns, whereas their functional analogs U11, U12,
U4atac and U6atac snRNP, respectively, form the minor
(U12-type) spliceosome. U5 snRNP is present in both com-
plexes (reviewed in 11,12).
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The spliceosome recognizes primarily conserved sequences
at intron boundaries: the 5′-splice site (ss), the 3′-ss, the
branch-point sequence (BPS) and the poly-pyrimidine tract
(poly-Py) (reviewed in 11). In vitro, and possibly in vivo,
the spliceosome assembles on these signals in a step-wise
manner, through the following different complexes: E, A, B,
B∗ and C (Supplementary Material, Fig. S1) (reviewed in
11). Joining of the U4/U6.U5 snRNP particle (the tri-snRNP)
to complex A (prespliceosome) leads to its conversion into the
precatalytic complex B. Major compositional and confor-
mational rearrangements are needed for the catalytic acti-
vation of the spliceosome. These involve the release of U1
and U4 snRNPs together with U4/U6 snRNP-associated pro-
teins, following U4/U6 unwinding. These changes result in
the formation of complex B∗ (activated spliceosome), which
undergoes the first step of splicing to generate the catalytic
complex C. The latter complex is then further rearranged to
allow the second catalytic step to occur. Once pre-mRNA spli-
cing is completed, the spliceosome disassembles, U snRNPs
are recycled for additional rounds of splicing and the mRNA
is released as an mRNP (reviewed in 11).
The RP-related splicing proteins have been proved to be
part of the tri-snRNP (Supplementary Material, Fig. S1)
(13,14), a particle essential for the major and minor spliceo-
somes (8,15,16). However, the precise mechanism by which
defects in these essential spliceosome components result in
RP has so far remained obscure.
In this work, we analyze the function and the composition
of spliceosomes in human cells with PRPF31, PRPF3 and
PRPF8 mutations and propose a model linking generalized
pre-mRNA splicing deficiency and hereditary retinal degener-
ation. Since PRPF animal models have so far failed to provide
conclusive answers (17–19) and since retinal biopsies to
examine photoreceptors directly are not an ethically sustain-
able option, we took advantage of the widespread expression
of these splicing factors and the common function of the spli-
ceosome across tissues to perform in vitro and ex vivo studies
in lymphoblasts from patients with 10 different mutations in
all three RP-PRPF genes. Using this approach, we document
that mutations in RP-PRPF genes alter the levels of snRNAs
and cause defects in generic and AS. Our findings therefore
reveal that RP-PRPF genes can selectively affect splicing
decisions and indicate that RP may be a splicing disease to
which retinal cells are most sensitive.
RESULTS
Retina expresses the highest amount of spliceosomal
snRNAs and processes the largest volume of pre-mRNAs
We quantified snRNAs in a panel of five human tissues
(including retina) and two cell lines. Our results, normalized
to 18S and 28S rRNAs, showed that retina expressed approxi-
mately seven times more major snRNAs than the other tissues
tested and approximately two times more of these molecules
than highly proliferative human cell lines (Fig. 1A). In
addition, it expressed roughly twice as many minor snRNAs
when compared with the other samples, with the exception
of testis, which displayed comparable amounts (Fig. 1B).
To test whether the high level of snRNAs in retina was
related to the volume of pre-mRNA splicing, we computed
the amounts of 2255 processed housekeeping transcripts (Sup-
plementary Material, Table S1) across 31 human tissues using
available expression microarray data (20). We found that
retina produced the highest amounts of spliced transcripts
(Fig. 1C).
Although these data were obtained by completely unrelated
procedures and on different primary samples, the levels of
major spliceosome snRNAs and of spliced housekeeping
genes (containing mostly U2-type introns) correlated very
well across tissues (compare Fig. 1A and C).
RP-PRPF mutations
We obtained lymphoblast cell lines from 13 patients belonging
to families with dominant RP and with distinct mutations in
RP-PRPF genes (Supplementary Material, Table S2). In all
downstream experiments, data were obtained for at least two
independent mutations per RP-PRPF gene and for two distinct
controls. Whenever the results were identical for different
mutations within the same gene, representative results for
one of them are shown.
Altered snRNP levels and relative composition of the
tri-snRNP in cells with mutations in PRPF31, PRPF3 or
PRPF8
To detect any abnormalities in the migration and composition
of spliceosome components, we fractionated nuclear extracts
from cell lines of patients with RP-PRPF mutations (Sup-
plementary Material, Table S2) in 10–30% glycerol gradients.
snRNAs from the major and the minor spliceosomes were
visualized by northern blotting and their relative amounts
determined by densitometry (Fig. 2). Comparison of nuclear
extracts from control lymphoblasts and HeLa cells showed
that all snRNAs studied had the same distribution across the
gradient (Fig. 2 and data not shown). The fractionation of
RP-PRPF extracts revealed a distribution of snRNAs that
was comparable with controls (Fig. 2A) and indicated that
snRNPs had similar molecular weights. Nevertheless, by quan-
titative assessment of snRNA amounts (normalized to U1
snRNA), we found that U2 snRNA was reduced by 13–
18% in all RP-PRPF extracts relative to the controls
(Fig. 2C). The amounts of snRNAs composing tri-snRNPs
were even more reduced in these extracts: RP-PRPF extracts
had 63–76% of U4 snRNA, 52–63% of U5 snRNA and
53–74% of U6 snRNA (Fig. 2C). The amounts of minor
snRNAs did not appear to be globally affected in RP-PRPF
cells, with the exception of U4atac and U6atac in cells with
PRPF8 mutations (Fig. 2C), where they were reduced by 20
and 44%, respectively, compared with controls. We also
assessed the distribution of a subset of tri-snRNP proteins by
fractionation in glycerol gradients (Fig. 2B) or by immunopre-
cipitation from total extracts (Supplementary Material,
Fig. S2). In all extracts tested, tri-snRNP components accumu-
lated in fractions 18–21 of the gradient (Fig. 2).
In cells with PRPF31 mutations, glycerol gradient revealed
no qualitative change in the distribution of the tested
tri-snRNP proteins (Fig. 2B). The immunoprecipitation
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showed, however, that all tri-snRNP proteins tested were
present at 60% with respect to controls (Supplementary
Material, Fig. S2). Since this deficit was not due to their
overall reduced availability in the cells (Supplementary
Material, Fig. S3), our data suggest that lymphoblasts with
PRPF31 mutations correctly assembled tri-snRNPs, but in a
less efficient manner compared with controls. However, this
phenomenon was not immediately visible in glycerol gradient
experiments, probably because of the lower sensitivity of the
western procedure to detect small amounts of proteins
present in individual fractions.
In cells with PRPF3 mutations, PRPF3 accumulated in frac-
tions containing tri-snRNPs and was absent elsewhere, indicat-
ing that mutant PRPF3 proteins stably associated with
tri-snRNPs (Fig. 2B). In contrast to the other tri-snRNP pro-
teins tested, PRPF4, hBrr2 and hSnu114 showed an altered
distribution, as they were also present in the lower molecular
weight fractions (Fig. 2B). Quantification of immunoprecipi-
tated tri-snRNP proteins showed that only 50% of PRPF4
was associated with snRNPs, compared with the control (Sup-
plementary Material, Fig. S2). Similarly, hBrr2 and hSnu114
proteins were also present in reduced amounts (30% and
50%, respectively, Supplementary Material, Fig. S2).
Glycerol gradient analysis of RP-PRPF8 extracts showed an
absence of PRPF8 in fractions lighter than those specific to U5
or the tri-snRNP (Fig. 2B), suggesting that both wild-type and
mutant proteins are present in U5 and the tri-snRNPs. Notably,
hBrr2, hSnu114 and PRPF6 displayed an altered distribution
(in addition to their presence in fractions 18–21), likely indi-
cating an impaired interaction with mutant PRPF8. Immuno-
precipitation showed that, relative to the control, only
10% of hBrr2, 50% of hSnu114 and 80% of PRPF6
were associated with the snRNPs (Supplementary Material,
Fig. S2).
Figure 1. Human retina expresses more snRNAs and processes the highest amounts of housekeeping transcripts. Relative amounts of snRNAs in various tissues,
as assessed by northern blotting with probes against major (A, bottom) or minor (B, bottom) spliceosomal snRNAs, are shown. Densitometry analyses are pro-
vided on the top panels. (C) Evaluation of the expression of 2255 housekeeping genes across 31 human tissues revealed that retina produces the highest amount
of constitutive mRNAs. The ‘gene expression score’ indicates the number of instances for which a given gene was maximally expressed in a tissue.
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Spliceosome assembly is delayed in extracts from patient
cell lines
Altered levels of snRNAs suggest that some aspects of spli-
ceosome formation and function may be affected. To investi-
gate this possibility, we assessed in vitro spliceosome
assembly in nuclear extracts from lymphoblasts by using
RNA1, a model pre-mRNA that contains all necessary splicing
signals (21) (Supplementary Material, Fig. S4A). Extracts
from control lymphoblasts followed the same kinetics of spli-
ceosome assembly as HeLa extracts, which are commonly
used in this type of assay (Fig. 3A). Conversely, extracts
from lymphoblasts with RP-PRPF mutations showed slower
kinetics of complex A accumulation, with maximal level of
assemblies appearing later than in controls (Fig. 3A,
arrows). In addition, formation of complexes B and C was
inefficient; catalytic complex C is normally visible after
30 min in control reactions, but was barely detected in extracts
from patients even after 120 min (Fig. 3A). Our results indi-
cate that nuclear extracts from patient cells can form spliceo-
somes in vitro, although the process has reduced kinetics.
The observed delay in complex A accumulation may be
direct or caused by its altered conversion into downstream
structures. To distinguish between these possibilities, we
assembled splicing complexes using a mutant RNA1 lacking
the 5′-ss (Supplementary Material, Fig. S4B), and onto
which spliceosome assembly is blocked at the level of
complex A (22). As shown in Figure 3B, all extracts
reached the peak level of complex A at 15 min, suggesting
that the delay in spliceosome formation in cells with
RP-PRPF defects is due to a defect occurring after complex
A. The above observations suggest that conversion of
complex A into complex B is defective in RP-PRPF cells
and that this defect impacts the kinetics of accumulation of
complex A and the efficiency of all subsequent
tri-snRNP-dependent steps.
Pre-mRNA splicing is affected in lymphoblasts carrying
RP-PRPF mutations
To assess whether defects in spliceosome composition
and assembly affect processing of pre-mRNA, we performed
in vitro splicing assays using RNA1 as substrate. Although
all nuclear extracts tested could splice this pre-mRNA,
samples from patient lymphoblasts showed a reduced splicing
efficiency (Fig. 4).
Because of the splicing defect observed in vitro, we then
tested splicing of endogenously expressed transcripts in lym-
phoblast cells by reverse transcription polymerase chain reac-
tion (RT-PCR) using primers that allowed the simultaneous
amplification of both spliced and unspliced products. Since
mammalian splicing signals are degenerate, we selected a
Figure 2. Glycerol gradient fractionation reveals alterations of tri-snRNP composition in RP-PRPF lymphoblasts. Nuclear extracts from control or patient lym-
phoblasts, as indicated on the top of the figure, were fractionated in parallel on 10–30% glycerol gradients. Fractions were collected from the top to the bottom of
the gradient and processed as follows. (A) RNA was extracted and analyzed by northern blotting. Identities of detected snRNAs are shown on the left.
(B) Proteins (indicated on the left) present in each fraction were visualized by western blotting. The tri-snRNP-containing fractions are indicated on the
bottom of the panel (solid, horizontal bars). Arrows indicate tri-snRNP proteins abnormally distributed across the gradient, with respect to the control. (C) Den-
sitometry measurements of northern blots were normalized to the measured U1 snRNA amounts. Quantity of the each snRNA is expressed as a ratio to the
corresponding snRNA in control lymphoblasts (average+ standard deviation) and as percent of control values, in parentheses.
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panel of 57 introns recapitulating typical sequence motifs
found in the human genome, including targets for U2 and
U12 spliceosomes (Supplementary Material, Table S3). Fur-
thermore, for each intron type, we scored conservation of
different splicing elements. Although none of the introns
tested belonged to specific RP genes, they carried splicing
signals that are present in such genes. As many as 5 out of
57 splicing units (8.8%) accumulated unspliced products in
cells from patients with RP-PRPF mutations (Fig. 5). For
two of these, we observed a gene-specific splicing defect
(i.e. intron 8 of MATN4 and intron 1 of CBLN1). However,
this effect was not (within the same PRPF gene) mutation
specific and seemed not to depend on the type of intron
tested (Supplementary Material, Fig. S5).
Alternative splicing is affected in RP-PRPF cells
Splice site selection often relies on kinetic choices. The slow-
down of specific tri-snRNP-dependent steps of spliceosome
assembly on competing pairs of splice sites may favor the
use of one combination over another; likewise, a change in
the stoichiometry of snRNAs may also influence the choice
of alternative splice sites (23). We investigated whether AS
could be affected in RP-PRPF cells. We therefore analyzed
the splicing pattern in 13 cell lines with RP-PRPF mutations
and 11 control lymphoblasts using a RT–PCR platform that
interrogated 96 alternative splicing events (ASEs). Each test
was designed to detect a long and a short isoform. For each
ASE, we computed its specific percentage of splicing index
(PSI), defined as the ratio between the long isoform over
the sum of the short and long isoforms. When more than
two products were observed, the short and long products
were selected to maximize their total abundance across the
reaction set.
Considering a false discovery rate of 0.15, three significant
scores were obtained for cell lines bearing PRPF31 mutations
for genes AXIN1, BCL2L11 and HSC20 (Fig. 6A; all splicing
profiles and electropherograms can be consulted on http://
palace.lgfus.ca). The analysis of the four RP-PRPF8 and
three RP-PRPF3 cell lines yielded no ASEs harboring
Figure 3. Kinetics of spliceosome assembly is delayed in cell lines from patients with RP-PRPF mutations. Nuclear extracts from HeLa and lymphoblast cells, as
indicated on top of the panels, were mixed with in vitro-transcribed radiolabeled RNA1 RNA (A) or its mutant version lacking the 5′-ss (B) and incubated under
splicing conditions. At indicated time points, the reactions were stopped, and complexes resolved by native 4% (A) or 5% (B) PAGE and visualized by auto-
radiography. Identity of the spliceosome complexes A–C and the free RNA is indicated on the right. Complex H is formed upon binding of hnRNP proteins to
RNA and is not specific to the spliceosome. Arrows show the maximal amount of complex A in each assay.
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significant q-values. However, the limited number of available
(different) cell lines for these two latter RP-PRPFs would not
allow a confident detection of significant events, unless these
caused very large effects.
Since mutated RP-PRPF proteins may promote aberrant
splicing and produce novel splice isoforms, we inspected our
data for the occurrence of novel RT–PCR products that
might be associated with these conditions. With the caveat
that none of these products has been confirmed to be a mis-
splicing event, we noted that the RT–PCR product at 175 bp
for the APP transcript was strikingly more prevalent in
RP-PRPF31 samples than in controls and other RP-PRPF
samples (Fig. 6B). The 379 bp product for FGFR1 was
detected only in three cell lines with PRPF31 mutations but
never in controls or other RP-PRPF cell lines (Fig. 6C). The
665 bp and 793 bp products of TNFRSF10B (also known as
TRAIL-R2) were detected in most cells with RP-PRPF
defects and never in controls (Fig. 6D). While the 337 bp
product of BMP4 was less abundant in most samples with
PRPF31 and PRPF8 mutations, the 195 bp product showed
opposite behavior (Fig. 6E). Finally, the 378 bp product for
UTRN was detected only in RP-PRPF31 and RP-PRPF8 cell
lines, but not in the other samples (Fig. 6F).
Depleting PRPF8 in human cell lines alters alternative
splicing
All RP-PRPF cell lines analyzed were derived from patients
with heterozygous mutations, hence always bearing a wild-
type allele expressing a functional protein product. For this
reason, the biological defects detected in cells from patients
with naturally occurring mutations may be subtle and/or
obscured by the activity of this functional allele. To circum-
vent this masking effect, we stressed the experimental
system by provoking a stronger RP-PRPF deficiency. We
chose to deplete PRPF8 by siRNA, since this protein has
been shown to play a central role in the splicing process
(24) and, unlike PRPF31 and PRPF3, it is present during the
catalytic steps of intron excision.
The same set of 96 previously described ASEs was analyzed
following PRPF8 depletion in five cell lines: MCF-7,
MDA-MB-231, PC-3, OVCAR-3 and SKOV3. Depletion effi-
ciencies were determined using quantitative PCR (qPCR) and
were considered adequate only if the depletion was superior to
50%. For tests satisfying this condition, a △PSI value, defined
as PSIknockdown 2 PSIcontrol, was computed. From over 1000
△PSI values collected, nearly one-tenth had values greater
than 10 percentage points with both siRNAs when all five
cell lines were considered (Table 1). A 10% change in PSI
provides a Z-score above 1.5, which represents 1.5 standard
deviations above or below the average variation observed for
thousands of controls performed for all splicing units in
these cell lines (25). The proportion of units that shifted
upon depleting PRPF8 ranged from 10% for MCF-7 cells
to nearly 30% for SKOV3, but such variations may be due
to the depletion efficiencies. The hit overlap across all cell
lines was considerable, with over half (26/49) of the shifted
ASEs occurring in two or more cell lines. Eight units
(APG5L, DDR1, F3, FANCA, PPP3CB, PTPN13, SHMT1
and TNFSFR10B) reacted similarly to PRPF8 depletion in at
least four of the five cell lines. These results demonstrate
that reducing the level of PRPF8 in mammalian cells can
alter the AS of numerous genes, and that a substantial fraction
of these effects are common to cell lines of different origins.
DISCUSSION
Despite recent fundamental research performed in yeast or
standard laboratory cell lines, the molecular link between
Figure 4. In vitro pre-mRNA splicing is less efficient in extracts from patients with RP. Nuclear extracts from HeLa and lymphoblast cells, as indicated on the
top (pt, patient), were used in in vitro splicing assays with radiolabeled RNA1 RNA as substrate. At indicated time points, RNA was extracted from the reactions,
separated by 8% polyacrilamide/8.3 M urea gels and visualized by autoradiography. Migration of pre-mRNA and of its splicing products is indicated on the right.
The radiolabeled molecular weight marker (M, in nt) is shown on the left. no NXT: no nuclear extract.
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RP-PRPF proteins and the pathogenesis of retinitis pigmentosa
has not been fully clarified. By quantification of major and
minor snRNAs, we unexpectedly found that the retina nor-
mally expresses up to 7-fold more major snRNAs and approxi-
mately twice as many of the minor snRNAs compared with
other human tissues. The higher level of snRNAs in the
retina is a likely consequence of another surprising result;
i.e. this tissue contains the highest volume of processed pre-
mRNAs within the whole body, as measured by the amount
of spliced genes that were common to 31 human tissues.
These results suggest that a deficiency in spliceosome com-
ponents would be more deleterious for the retina than for
other human tissues.
To explore the nature of this potential defect leading to RP,
we used lymphoblast cell lines derived from patients with RP
with 10 different mutations in all 3 RP-PRPF genes. Glycerol
gradient centrifugation of nuclear extracts revealed alterations
in the stoichiometry of the snRNAs, as well as altered
tri-snRNP protein composition, in cells carrying RP-PRPF
mutations. Relative to U1 snRNA, U2 snRNA was reduced
by 13–18%, while tri-snRNAs were decreased up to 50%.
Minor snRNAs were also decreased but only for U4atac and
U6atac in RP-PRPF8 cells. Quantitative assessment of
tri-snRNP protein composition by immunoprecipitation indi-
cated that cells from patients with PRPF31 mutations
assembled roughly half of these particles with respect to con-
trols. These data are in agreement with previous work showing
that PRPF31 alleles causing RP result in short-lived or absent
mRNAs and therefore in no mature protein (26–28). Conse-
quently, in these cells, only the wild-type allele can provide
functional protein. Although the observed defects are less pro-
nounced compared with complete RNAi-mediated depletion
of PRPF31 in HeLa cells (29), they are in agreement with
the described essential role of PRPF31 in tri-snRNP assembly
and spliceosome formation (29–31).
Unlike defects in the PRPF31 gene, PRPF3 and PRPF8
mutations are predicted to yield stable mutant proteins that
are co-expressed in heterozygotes with their wild-type
counterparts (2,3). Our results support this idea: comparable
amounts of PRPF3 and PRPF8 were identified in nuclear
extracts from patient and control lymphoblast cells. In
addition, glycerol gradient fractionation and immunoprecipita-
tion experiments showed that both mutant and wild-type
PRPF8 and PRPF3 proteins were stably associated with
tri-snRNPs in the corresponding cell lines. Tri-snRNPs
bearing the PRPF3 and PRPF8 mutant proteins did assemble
and had similar molecular weights to those of controls, but
contained reduced amounts of hSnu114 and hBrr2. Since the
two latter proteins are involved in U4/U6 and U4atac/
U6atac snRNA unwinding (32–35), our results suggest that
RP-PRPF3 and RP-PRPF8 mutations could affect this
process, necessary for the catalytic activation of the spliceo-
some. In agreement with our results, it has been demonstrated
that the yeast homolog of PRPF8-R2310G (one of the mutant
PRPF8 forms analyzed here) impairs U4/U6 snRNA unwind-
ing by Brr2, resulting in the disregulation of catalytic
Figure 5. Splicing of a subset of introns is impaired in metabolically active lymphoblasts with RP-PRPF mutations. RT–PCRs were performed to analyze con-
stitutive splicing events on transcripts extracted from living lymphoblasts (from controls and patients, ‘pt’) and bearing a variety of splicing signals. Splicing
units that were not correctly spliced are shown. Histone H3 is a positive amplification control. Identity and sizes of the PCR products are indicated on the
right of the figure. Exons containing the PCR primers are indicated by ‘E#’. Migration of unspliced RT–PCR products is indicated by asterisks. Sizes of the
molecular weight markers (M, in bp) are indicated on the left.
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Figure 6. Impact of PRPF mutations on the splicing profiles of selected ASEs. (A) Three ASEs that reacted to the presence of mutations in PRPF31. The box-
plots depict inclusion percentage (PSI or percent splicing index) for known alternative exons for individual ASEs. The boxes include values in the first to third
quartiles; the thick horizontal line indicates the median; whiskers extend to data points at or less than 1.5 times the interquartile range. Circles are outliers.
q-values are indicated on the x-axis. (B–F) Graphical representation of the relative abundance of all RT–PCR products obtained for selected ASEs using lym-
phoblast cell lines derived from controls or patients with RP-PRPF mutations. The size of the products is indicated in the legend (in bp).
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Table 1. Impact of PRPF8 on the AS of 96 ASEs
AKAP13 APAF1 APC APG5L APP AXIN1 AXL BCAS1 BCL2L1 BTC C11orf4 C1orf16 CAPN3 CHEK2 DDR1 NALP1 DNMT3B
MCF7 siPRPF8_1 210.3 227.2 1.5 227.1 23.8 1.2 28.0 227.1 10.6 220.2 224.9
siPRPF8_2 21.7 2.7 24.6 11.4 3.2 14.3 4.7 0.7 8.4 6.0 24.8 215.8 213.1 26.3
MDA-MB-231 siPRPF8_1 215.0 216.2 212.5 220.2 25.3 7.3 0.8 230.1 25.4 215.6 225.7 21.5 4.3 233.6 222.4 218.4 23.9
siPRPF8_2 24.4 27.0 28.0 214.5 22.9 34.9 12.7 28.1 25.7 225.1 21.5 0.3 218.0 221.2 218.2 23.9
OVCAR-3 siPRPF8_2 220.6 27.6 240.0 217.7 27.9 8.2 27.5 2.6 211.2 24.6 28.0 20.6 218.8 28.1 213.1 213.8
siPRPF8_1 231.3 217.2 239.6 218.6 215.8 6.2 20.1 0.0 211.8 212.4 212.3 28.9 27.6 221.5 219.3
PC-3 siPRPF8_1 (exp1) 236.0 224.0 222.4 241.3 223.1 9.8 26.9 6.4 26.4 228.3 231.0 27.5 224.0 213.3 214.9 220.7 213.8
siPRPF8_2 (exp1) 212.8 218.6 224.6 220.3 28.8 17.8 9.1 6.4 25.3 228.1 23.1 28.3 220.8 213.2 20.4 22.2 215.8
siPRPF8_1 (exp2) 229.0 238.8 215.5 234.1 226.6 19.5 1.6 225.3 218.0 226.4 0.4 0.0 225.9 232.7 215.0 22.8
siPRPF8_2 (exp2) 29.0 213.3 210.0 223.2 216.8 24.3 6.7 224.6 222.4 23.2 22.9 0.0 223.0 228.8 29.2 25.6
SKOV3 siPRPF8_1 29.3 228.0 247.7 214.1 24.1 17.0 2.7 22.7 219.6 213.0 28.1 210.6 211.7 218.8 224.7 236.4 22.9
siPRPF8_2 28.0 229.9 248.0 210.4 22.9 17.2 8.1 18.6 217.8 27.8 27.5 211.9 27.9 214.1 219.9 222.7 22.9
DRF1 F3 FANCA FANCL FGFR1OP FGFR2 FGFR4 FN1 FN1 FN1 HMGA1 HMMR HSC20 LGALS9 LIG3 MAPT MCL1
MCF7 siPRPF8_1 1.6 25.2 219.1 4.5 13.2 12.9 2.8 2.3 8.0 20.4 38.9 19.9 28.7 220.5
siPRPF8_2 9.0 7.0 3.6 33.7 16.3 45.6 29.6 5.1 20.4 18.5 14.1 8.2 20.2 24.5 30.3 0.3 7.7
MDA-MB-231 siPRPF8_1 218.3 214.7 210.8 25.3 15.0 221.6 1.8 23.3 12.5 9.4 229.5 225.5 15.8 23.2 220.8 213.4
siPRPF8_2 213.9 213.7 215.1 20.4 12.7 0.4 1.2 14.9 9.9 212.9 221.0 23.2 2.1 22.0 25.5
OVCAR-3 siPRPF8_2 27.6 212.1 214.5 11.9 12.0 14.9 211.0 3.9 211.0 8.6 10.2 23.1 28.9 21.9 0.9 22.9 24.0
siPRPF8_1 28.8 214.9 225.9 22.5 15.1 24.7 1.9 215.2 17.5 8.3 211.1 215.9 4.9 24.8 26.7 25.6
PC-3 siPRPF8_1 (exp1) 227.5 212.3 215.1 22.4 12.7 10.4 19.7 22.0 11.5 6.4 213.9 43.9 6.3 236.3 217.3
siPRPF8_2 (exp1) 212.2 216.7 223.1 1.7 2.3 25.7 1.8 28.1 17.7 17.5 22.6 211.2 0.1 2.0 220.8 214.0
siPRPF8_1 (exp2) 216.1 227.3 223.5 5.0 11.7 69.1 8.0 12.9 22.8 13.6 21.9 22.5 24.7 26.8 215.2 214.2
siPRPF8_2 (exp2) 216.5 224.4 237.2 210.7 9.3 49.1 2.7 26.9 17.1 15.8 21.2 28.1 22.6 23.9 210.2 214.3
SKOV3 siPRPF8_1 6.5 235.2 218.3 10.6 24.7 18.1 29.4 33.2 7.8 31.8 23.8 1.0 225.4 217.8 2.6 23.1 26.7
siPRPF8_2 8.6 235.0 217.6 12.3 20.9 8.0 15.5 23.1 25.5 36.1 24.9 3.8 225.3 236.7 22.2 22.1 29.6
PCSK6 POLB POLI PPP3CB PTPN13 PTPRB RUNX2 SHMT1 SPP1 SYK SYNE2 TNFRSF10B TOPBP1 TSSC4
MCF7 siPRPF8_1 214.6 9.9 223.1 28.6 218.0 211.1 228.2 0.0 26.7 13.7
siPRPF8_2 25.7 21.4 0.6 223.0 26.1 211.1 3.3 9.1 3.1 30.9 19.2 17.2
MDA-MB-231 siPRPF8_1 7.2 10.4 232.0 230.2 234.2 27.3 218.4 28.0 239.0 2.2 34.6 9.7 4.8
siPRPF8_2 252.3 11.1 26.8 232.0 224.4 2.8 25.5 223.1 211.0 6.1 11.7 38.8 9.4 2.3
OVCAR-3 siPRPF8_2 212.3 11.1 17.8 218.7 213.0 218.1 216.0 210.0 219.1 22.6 3.6 22.6 7.9 15.7
siPRPF8_1 12.8 20.1 18.5 218.7 214.3 216.1 213.1 215.6 0.7 225.5 24.4 22.6 2.6 11.8
PC-3 siPRPF8_1 (exp1) 9.9 11.8 248.6 233.8 253.7 212.3 26.1 257.3 213.3 37.7 24.1 10.3
siPRPF8_2 (exp1) 38.3 4.9 6.6 240.3 228.0 236.1 214.9 213.3 220.4 23.3 33.8 35.8 3.6 1.1
siPRPF8_1 (exp2) 18.2 8.9 225.7 236.4 23.1 218.8 250.3 250.9 212.5 41.4 6.9 12.4
siPRPF8_2 (exp2) 13.5 20.3 225.6 234.8 23.6 223.8 222.9 225.6 32.3 32.6 3.7 7.1
SKOV3 siPRPF8_1 222.0 211.7 13.0 232.4 218.8 213.6 211.8 217.5 225.4 220.3 24.8 47.0 8.7 31.5
siPRPF8_2 219.8 215.6 14.1 232.3 215.6 24.5 215.3 218.9 218.0 29.4 33.3 44.6 8.8 29.5
The table only lists ASEs that reacted to the depletion of PRPF8 in at least one of the cell lines tested.△PSI values are given for each of the two siRNAs tested. Empty squares with no value indicate that no products
were detected. The experiment on PC-3 cells was repeated on a different day and yielded very good reproducibility (Pearson’s correlation coefficients of 0.867 and 0.830 for si1 and si2, respectively). Dark gray
squares indicate that all samples from a given cell line (or at least three out of four for PC-3) yielded a change superior to 10% relative to controls done on the same day. To access all the data of the experiment, go to
http://palace.lgfus.ca/ to obtain an interactive version displaying the compilation and individual electropherograms.
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activation of the spliceosome (36). Impairment of the
tri-snRNP assembly has been observed by Boon et al. (37)
in a yeast strain carrying the same mutation. The observed
alterations in the stoichiometry of U4, U5 and U6 snRNAs
in human cells with PRPF8-R2310G could indicate that a
similar dysfunction may also be happening in these cells,
although at steady-state we observe most of the U4 and U6
(or their minor spliceosome counterparts) in the tri-snRNP-
containing portions of the gradient.
Tri-snRNPs containing mutant PRPF3 proteins are also par-
tially devoid of PRPF4 (50%), whereas those containing
mutant PRPF8 partially lack PRPF6 (75%). Both PRPF4
and PRPF6 play a role in the tri-snRNP assembly
(29,31,38,39) and have been shown to have an additional role
in the catalytic activation of the spliceosome (14,40–42).
To investigate whether alterations in the stoichiometry of
spliceosome components elicited defects in its formation, we
performed in vitro assembly assays. Our analysis in nuclear
extracts from patient lymphoblasts showed a substantial
delay in the formation of the splicing complex A. This may
be the consequence of a slower formation of complex A due
to lower U2 snRNA and, indirectly, U2 snRNP amounts.
Alternatively, a reduced conversion rate of complex A into
complex B and downstream structures could occur because
of the observed tri-snRNP defects. In addition, we cannot
exclude that the rate of some proof-reading mechanism that
dissociates or degrades abnormal B or C complex assemblies
is faster than that of full spliceosome formation, preventing
the accumulation of early complexes.
Together, our results from glycerol gradient fractionation,
immunoprecipitation and in vitro spliceosome assembly show
that all RP-PRPF mutations included in this study delay
spliceosome assembly, but may act through different molecular
mechanisms. While PRPF31 mutations likely affect tri-snRNP
formation directly, PRPF8 and PRPF3 mutations could
indirectly impair both U4/U6.U5 assembly and the catalytic
activation of the spliceosome. However, in cell lines from
patients, these defects did not lead to aberrant localization of
RP-PRPF proteins and their interacting partners (Supplemen-
tary Material, Figs S6 and S7) or to spliceosome destabilization
due to putative protein decay (Supplementary Material,
Fig. S3), in contrast to what has been observed after exogenous
overexpression of mutant PRPF31 protein in HeLa or PRPF3 in
photoreceptor-derived murine cells (43,44). The observed
defects are also less pronounced compared with the data
obtained using thermo-sensitive (haploid) mutant yeast or
siRNA-silenced cells (29,31,37), likely because patients are
heterozygotes and carry one fully functional copy of
RP-PRPF that prevents the complete block of the spliceosome.
Pre-mRNA splicing analyses in extracts from patients
showed that the observed defects in spliceosome composition
translated into a reduction in splicing activity. Although the
splicing process itself was not abolished (as expected, since
heterozygous RP-PRPF mutations are not lethal), its effi-
ciency was reduced. This is probably a direct consequence
of observed defects detected in vitro with extracts bearing
PRPF mutations. While it is difficult to extrapolate these
results to an in vivo context, it is plausible that RP-PRPF
mutations can cause a systemic splicing defect in patients. In
support of this view, we showed that 8.8% of the introns
from naturally expressed genes (summarizing different assort-
ments of splicing signals) displayed dramatic splicing pro-
blems in lymphoblasts from patients. This value may be
even higher considering that our experimental setup did not
take into consideration the counteracting effect of nonsense-
mediated decay, a cellular sentinel eliminating many abnor-
mally spliced transcripts. The mis-spliced transcripts identified
in this study, selected mainly because of their intronic splicing
motifs, are likely not directly involved in RP pathogenesis.
However, they clearly indicate that cells with RP-PRPF
mutations display transcript-specific defects, in agreement
with data from yeast (45) and human cells (46). The nature
of the signal, motif or structure that confers responsiveness
to defective PRPF proteins remains for the moment unknown.
The analysis of AS in RP-PRPF cells identified alterations in
splicing patterns in a subset of the transcripts analyzed. Although
all of them seemed to be expressed in the retina according to
online databases, it is difficult to find a direct link between
these transcripts and RP. It is perhaps worth noting that mutations
in the zebrafish homolog of AXIN1 result in dwarfed or absent
eye development (47). However, this ocular phenotype is clini-
cally different from RP, and therefore this finding may have no
particular meaning from a mechanistic point of view. The
effects of PRPF8 depletion on ASEs were more pronounced
compared with the partial RP-PRPF deficiencies displayed by
heterozygous cell lines. When the beneficial effects of wild-type
PRPF8 were removed, 10% of the investigated transcripts
displayed changes in AS pattern in at least four of the five cell
lines depleted of PRPF8.
Although tri-snRNP is a constitutive splicing factor,
reduction in its level or its composition may also impact AS.
Direct effects on AS may occur because of the observed slow-
down of specific U4/U6.U5-dependent steps of spliceosome
assembly on competing pairs of splice sites. Similarly, it
was demonstrated that mutations in the RNA portion of the
constitutive splicing factor U1 snRNP can change its affinity
for competing splice sites and alter splice site selection (48).
Likewise, mutations in SMN, a protein component essential
for the snRNP maturation machinery, change the stoichi-
ometry of snRNAs and promote defects in the AS of numerous
transcripts (23). Also, down-regulation of constitutive splicing
factors U2AF65 and PUF60 in mammalian cells and core spli-
ceosome components in Drosophila can alter the choice of
alternative splice sites (49–51). There may, however, be alter-
nate explanations. For example, altered tri-snRNP particles
may elicit secondary defects in the expression of one or
several splicing regulatory proteins. Secondary effects could
also alter the expression of a factor unrelated to splicing that
is involved in differential mRNA stability, thereby changing
the relative proportion of different splice forms.
Remarkably, changes in AS patterns in RP-PRPF cells and
upon PRPF8 knock-down also suggest that late steps of spli-
ceosome function can reprogram splicing decisions. In agree-
ment with this, the U5 snRNP-associated factors PRPF6 and
USP39 have recently been shown to affect the splice site
choice for several transcripts, including Mcl1 (52).
Although patients with RP-PRPF mutations have splicing
defects in their lymphoblasts and presumably in other tissues
as well, they show disease only in the retina, likely because
of a threshold effect determined by its high pre-mRNA
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splicing activity. These mutations may affect many tissues at
sub-pathological levels, or may not manifest their deleterious
effects within a human lifetime, whereas retinal cells could
undergo cell death due to an increased accumulation of aber-
rant mRNAs produced through impaired constitutive and/or
AS. Another model, which is not incompatible with the pre-
vious one, would rely on mechanisms involving selective mis-
splicing of one or a few RP genes (53,54), although specific
studies investigating this possibility have not analyzed
mRNA from non-ocular tissues (55,56), and recent results
have shown that processing of two transcripts important for
photoreceptor function in human cells is not affected by
RP-PRPF mutations (57). At the moment, our data cannot
unambiguously favor one model over the other, and the
precise mechanisms by which these defects lead to photo-
receptor cell death remain to be clarified.
In conclusion, autosomal dominant RP caused by mutations
in PRPF genes seems to be a generalized splicing disease that
may more dramatically affect a subset of pre-mRNAs. In
agreement with the observation that patients do not suffer
from syndromic symptoms and appear to have a normal life-
span (58), functional splicing defects are globally mild com-
pared with lethal PRPF knockouts in yeast and mammalian
cells. This picture is very similar to that recently shown for
another tissue-specific and progressive disorder, spinal muscu-
lar atrophy, which is caused by the systemic deficiency of
SMN, a protein that is essential for the biogenesis of
snRNPs (23). Our results indicate that future treatment strat-
egies for PRPF-linked RP should be aimed at correcting
pre-mRNA splicing impairment.
MATERIALS AND METHODS
Patients and cell culture
This study involved human subjects and was carried out in
accordance with the tenets of the Declaration of Helsinki
and was approved by the IRBs of the Massachusetts Eye
and Ear Infirmary, Harvard Medical School and University
of Lausanne. We recruited 13 patients with dominant retinitis
pigmentosa and mutations in PRPF31 (59), PRPF8 (60) or
PRPF3, as well as control individuals (14251, 13167, 14419,
29459, 29460, 13577, 13491). All patients were clinically
evaluated with an ophthalmologic examination including
visual field testing and electroretinography. Dominant inheri-
tance of the disease was inferred from family history and con-
firmed by the presence of two or more generations of affected
relatives. Upon signature of an informed consent, these indi-
viduals donated 10–50 ml of blood, from which lymphoblast
cells were obtained and cultured as described previously
(54). Lymphoblasts from patient AG0293, previously clini-
cally described (61), were purchased from the European Col-
lection of Cell Cultures. Control cells GM10858 were bought
from Coriell Cell Repository and cell lines H1, D1, K2 and E2
are from centre d’Etude du polymarphisme humain collection
(62).
The prostate cancer cell line PC-3 was grown in HAM’s
F12, the breast cancer cells MCF-7 in Minimum Essential
Medium Eagle’s, MBA-MB-231 cells in dulbecco’s modified
eagle’s medium (DMEM), the ovarian cancer cell line
OVCAR-3 in RPMI 1640 and the SKOV3 cell line in a 50/
50 mix of DMEM/F12. All media were supplemented with
10% fetal bovine serum (Wisent) (except OVCAR-3, which
contained 20%) and 2 mM L-glutamine.
Nuclear extracts
Lymphoblast cells in exponential growth (1 × 106 cells/ml)
were collected and nuclear extracts prepared as described pre-
viously (63,64). At least four different extracts were produced
for each cell line, starting from independent cultures. All
extracts yielded reproducible results in all tests reported.
Splicing-competent HeLa cell nuclear extracts were purchased
from Cilbiotech.
Immunoprecipitation and glycerol gradient fractionation
Nuclear extracts (150 mg each) were incubated overnight at
48C with 20 ml Protein G-Dynabeads (Invitrogen) coupled to
anti-Sm antibodies (Thermo Scientific). The beads were
washed six times with 1 ml of 20 mM Tris–HCl pH 7.4,
150 mM NaCl, 2.5 mM MgCl2, 0.05% Nonidet-P40 and
0.5 mM dithiothreitol (DTT). Bound material was eluted with
2× SDS sample buffer, proteins separated by 8% sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to nitrocellulose and visualized by
western blotting.
Glycerol gradient fractionation was performed as described
by Makarova et al. (31).
Northern blotting
Total RNA from human tissues (8 mg each, see below) or
RNA from glycerol gradient fractions were resolved in 10%
polyacrylamide/8.3 M urea gels, transferred to nylon mem-
branes and hybridized with major (65) and minor snRNA
probes (66,67). Plasmids encoding the major and minor
probes were kindly provided by Prof. Angela Kra¨mer and
Prof. Joan A. Steitz, respectively. All plasmids were linearized
according to the references, and probes were made by in vitro
transcription in the presence of 25 U SP6 RNA-polymerase
(U4 and U5 snRNA probes), or 25 U T7 RNA-polymerase
for the other probes (both from Promega), and 50 mCi
a-32P-UTP for 1 h at 378C, according to the protocol supplied
with the polymerases. The reactions were phenol/chloroform
extracted, and the RNA probes were precipitated with
ethanol and resuspended in RNase-free water. Hybridization
was performed as described (65).
Western blotting
Nuclear extracts (20 mg per sample), glycerol gradient frac-
tions or immunoprecipitated proteins were separated by 8%
SDS–PAGE, and proteins were transferred to a nitrocellulose
membrane and blotted as previously described (68). The fol-
lowing antibodies were used; primary antibodies: rabbit
anti-PRPF31 (26), rabbit and mouse anti-PRPF8 (Santa Cruz
Biotechnology), rabbit anti-PRPF3 (ProteinTech Group),
mouse anti-PRPF3 (Abnova), rabbit anti-PRPF6 (Santa Cruz
Biotechnology), rabbit anti-PRPF4 (ProteinTech Group),
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mouse anti-PRPF4 (Abnova), goat anti-hBrr2 (Santa Cruz
Biotechnology), rabbit anti-hSnu114 (Novus Biologicals),
rabbit anti-SF3a60 (69), mouse anti-SF3a66 (70), rabbit
anti-SF3a120 (71) and mouse anti-actin B (Sigma); secondary
antibodies: goat anti-rabbit-horseradish peroxidase (HRP)
(Jackson ImmunoResearch Laboratories), swine anti-rabbit-
HRP, goat anti-mouse-HRP and rabbit anti-goat-HRP (all
from Dako).
Densitometry and in silico analyses
Densitometry measurements of western blot signals were per-
formed with the ImageJ 1.410 software (NIH), and quantifi-
cation of northern blots was achieved either by the use of
Molecular Imager FX and the QualityOne-4.6.3 software
(BioRad), or ImageJ. Experimental uncertainty was expressed
as standard deviations of the values obtained, or as standard
errors. The analysis of 5′-ss, 3′-ss, BPS and poly-Py tract
was obtained either via the alternative splicing database
(ASD) workbench web interface (European Bioinformatics
Institute) or by retrieving pre-computed scores form the
ASD web site (72). Gene expression analysis in 31 human
tissues was performed on the data set defined by Dezso
et al. (20) for a subset of 2255 spliced housekeeping genes.
For a given gene, the expression was computed as the
average value over three tissue replicates. The ‘gene
expression score’ for each tissue represents a cumulative
count of occurrences for which a given sequence was maxi-
mally expressed and spliced in that tissue. For example, a
tissue ranking first for the expression of n genes out of 2255
would have a gene expression score equal to n.
In vitro spliceosome assembly and splicing
RNA1 (Supplementary Material, Fig. S4A) is derived from the
adenovirus Major Late transcription unit and was described
previously (21). A deletion mutant of RNA1 lacking the 5′-ss
(Supplementary Material, Fig. S4B) was derived from the
original plasmid; it contains 87 nucleotides upstream of the
3′-ss of intron 1 and 35 nucleotides of exon 2, up to the
ScaI site. Both plasmids, kindly provided by Prof. Angela
Kra¨mer, were linearized with ScaI and used as templates for
in vitro transcription with T3 RNA polymerase (Promega) in
the presence of 50 mCi of a-32P-UTP and 2 mM
m7G(5′)ppp(5′)G for 1 h at 378C, according to the instructions
supplied with the polymerase. Following transcription, tem-
plate DNA was digested with 2 U of RNase-free DNase for
15 min at 378C, the reactions were phenol/chloroform
extracted, precipitated with ethanol and RNA resuspended in
RNA sample loading buffer. Samples were loaded on 10%
polyacrylamide/8.3 M urea gels, and relevant bands were
excised, eluted and resuspended in RNase-free water.
Splicing complexes were assembled on RNA1 or its mutant
version (20 000 cpm/reaction of radiolabeled RNA) with
70 mg of nuclear extract in the presence of 2 mM ATP,
10 mM creatinine phosphate, 3 mM MgCl2, 20 U of RNasin
Plus, 1 mg of tRNA, 10 mM Hepes-KOH pH 7.9, 50 mM
KCl, 10% (V/V) glycerol, 0.1 mM ethylenediaminetetraacetic
acid (EDTA) and 0.25 mM DTT. The reactions were incubated
for 5, 10, 15, 30, 60 or 120 min at 308C and terminated by the
addition of heparin to a final concentration of 200 mg/ml and
incubation at room temperature for 10 min. Complexes were
resolved by native PAGE (concentrations indicated in the
figure legend) according to electrophoresis conditions
described previously (22), and visualized by autoradiography.
In vitro splicing reactions were performed with RNA1, as
described above. Instead of adding heparin, reactions were
treated with 4 mg of proteinase K in the presence of 2% sarco-
syl, 100 mM Tris–HCl pH 7.5, 20 mM EDTA, and 20 U of
RNasin plus for 15 min at 658C. Splicing products were
phenol/chloroform extracted, precipitated with ethanol, resus-
pended in RNA sample loading buffer, resolved in 8% poly-
acrylamide/8.3 M urea gels and visualized by autoradiography.
RNA samples and non-quantitative RT–PCR
Total RNA samples from cell lines were prepared by using
10 × 106cells and the RNeasy Mini kit (Qiagen), according
to the manufacturer’s instructions. RNAs from human retina,
brain, heart, testis and skeletal muscle were purchased from
Clontech; they represent pooled samples extracted from differ-
ent subjects and were described previously (73). cDNA was
made from these samples with oligo-dT primer, in the pres-
ence or absence (negative control) of reverse transcriptase as
described (73). Non-quantitative RT–PCRs were performed
with the Expand High Fidelity kit (Roche) with primers
listed in Table S4 and cycling conditions adapted to the
expression level of each transcript. Identity of each PCR
product was confirmed by direct DNA sequencing.
siRNAs and qPCR
The siRNAs used for knocking down PRPF8 were purchased
from IDT and their sequences were GAGAUAGGAGG
CAUUUCAATT for si1 and CGCCGAGAAAAAAGA-
GAUATT for si2. siRNAs were transfected into cells at a
concentration of 100 nM using Lipofectamine 2000 (Invitrogen).
RNA was extracted from mock-transfected and siRNA-
transfected cells 96 h post-transfection. To assess the
knockdown efficiency, we conducted quantitative real-time
RT–PCR assays using SyberGreen (Applied Biosystems).
Aldolase A (RTPrimerDB ID: 915) was used as the house-
keeping gene on the same samples. A total of 200 ng of
RNA measured for integrity (using the Agilent Bioanalyzer)
and quantification (using the Thermo Scientific NanoDrop)
was reverse transcribed using random hexamers (Roche)
with Transcriptor Reverse transcriptase (Roche) in a final
volume of 20 ml. Ten nanograms of cDNA were used for
the quantification in the presence of the specific primers at
0.2 mM in a 10 ml reaction in triplicates. Reactions were
carried out in the ABI 7500 qPCR (Applied Biosystems) or
Eppendorf Realplex. A first cycle of 10 min at 958C was fol-
lowed by 40 cycles of 15 s at 948C, 20 s at 558C and 20 s at
688C.
Splicing assays
A set of 96 AS units from various apoptotic and cancer-
related genes were selected from the AceView database.
Sets of primers mapping in the exons flanking the ASEs
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were designed using Primer3 with default parameters.
Primers were designed to cover alternatively spliced
regions such that two distinct splice products of sizes
ranging between 100 and 700 bp could be amplified. Our
analysis considered only ASEs annotated in public databases
such as NCBI, Ensembl and Aceview. For the global analysis
of splice isoforms in cancer cell lines, total RNA was
extracted using TRIzol and quantitated using the Bioanalyzer
station (Agilent Inc.). A total of 2 mg of RNA was reverse
transcribed using a mix of random hexamers and the Tran-
scriptor Reverse transcriptase (Roche) in a final volume of
20 ml. Twenty nanograms of cDNA were amplified with
0.2 U/10 ml of HotStarTaq DNA Polymerase (Qiagen) in
the buffer provided by the manufacturer, without extra
MgCl2 and in the presence of the specific primers (IDT)
for each splicing unit at 400 nM and dNTPs. The list of
units, oligos and expected size of RT–PCR products were
reported previously (25). Reactions were carried out in the
GeneAmp PCR system 9700 (Applied Biosystems). A first
cycle of 15 min at 958C was followed by 35 cycles of 30 s
at 948C, 30 s at 558C and 1 min at 728C. The reaction was
ended with an extension step of 10 min at 728C. Visualiza-
tion and analysis of amplified products were performed
using the LabChip HTTM DNA assay on an LC-90 automated
microfluidic station (Caliper) (74).
To assess the significance of our results, we used a stat-
istical approach tailored for the analysis of genomic data
that produces a q-value (75), with a false discovery rate
threshold of 0.15, indicating that only 15% of the results
judged to be significant could represent false positive
signals. In our case, this would correspond to less than
one hit.
Immunostaining and fluorescence microscopy
Lymphoblasts were grown on top of cover slips coated with
poly-L-lysine, fixed with 2208C methanol for 5 min and sub-
sequently washed three times with 1xPBS. The following anti-
bodies were used; primary antibodies: rabbit anti-PRPF31
(31), rabbit anti-PRPF8 (Santa Cruz Biotechnology), mouse
anti-SC35 (Sigma) and mouse anti-coilin (Sigma); secondary
antibodies: Texas Red-conjugated donkey anti-rabbit and flu-
orescein (FITC) conjugated donkey anti-mouse (all from
Jackson ImmunoResearch Laboratories). All antibodies were
incubated for 30 min at room temperature, with each incu-
bation step followed by washing steps (five times for 5 min);
all incubation and washing steps were done in 1xPBS contain-
ing 0.2% Nonidet-P40. Cells were mounted in Vectashield
mounting media (Vector Laboratories) and examined using a
Leica SP5 confocal microscope equipped with LAS 6000
AF software (Leica) and HCX PLAN APO 63x/1.40-0.60
NA/oil immersion lambdaBL objective. All images were
recorded sequentially for Hoechst, FITC and Texas red
emissions.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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